TrialJournal of Crohn's & colitis2016

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

David T Rubin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.